X0306 4 2022-05-09 0 0001630627 TREACE MEDICAL CONCEPTS, INC. TMCI 0001185249 TREACE JOHN R C/O TREACE MEDICAL CONCEPTS, INC. 203 FORT WADE ROAD, SUITE 150 PONTE VEDRA FL 32081 1 0 0 0 Common Stock 2022-05-09 4 S 0 37312 13.2984 D 1860478 I John R. Treace and Ginger D. Treace JTTEN Common Stock 2022-05-09 4 S 0 18966 14.2037 D 1841512 I John R. Treace and Ginger D. Treace JTTEN Common Stock 2022-05-09 4 S 0 18415 15.2157 D 1823097 I John R. Treace and Ginger D. Treace JTTEN Common Stock 2022-05-09 4 S 0 307 15.9665 D 1822790 I John R. Treace and Ginger D. Treace JTTEN Common Stock 408816 I As Co-Trustee of the John R. Treace Irrevocable Trust dated July 29, 2021 Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.93 to $13.86 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $13.93 to $14.86 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $14.93 to $15.891 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.96 to $15.97 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership of shares held in trusts for which his spouse is a co-trustee. /s/ Lisa Taylor as Attorney-in-fact for John R. Treace 2022-05-11